Table 2.
Second cohort PDTOs
| PDTO ID | Primary tumor or liver metastasis | RAS mutational status | Genomic profile (VHIO panel 300) | DSA/NGS result-based treatment decision |
|---|---|---|---|---|
| CR32 | Liver metastasis | Mutant | Not carried out | NA |
| CR33 | Primary tumor | Mutant | KRAS EXON 2 G13D, AMER1, PMS1, SOX9 | Mitomycin C plus 5-FU |
| CR34 | Liver metastasis | Mutant | Not carried out | NA |
| CR35 | Liver metastasis | Wild type | APC, ARID1B exon 16 AND ARID1B exon 20, TP53, EGFR, mTOR, BRCA1, CHD4, IRF2, TAF1, PI3KC2G, DICER1 | Nivolumab + SMAC mimetic (phase I trial) |
| CR36 | Liver metastasis | Not carried out | NA | |
| CR37 | Node metastasis | Wild type | APC, ATRX, HGF,BRCA2, NOTCH3, ROS1, TP53 | Olaparib off label |
| CR38 | Liver metastasis | Mutant | APC, ARIDB1, KRAS EXON 2 G12V, TP53 | FOLFOX plus bevacizumab |
| CR39 | Liver metastasis | Wild type | APC, TP53 | NA |
| CR40 | Liver metastasis | Mutant | Not carried out | NA |
5-FU, 5-fluorouracil; DSA, drug screening assay; NA, not available; NGS, next-generation sequencing; PDTO, patient-derived tumor organoid; SMAC, second mitochondrial-derived activator of caspases.